Hims & Hers Health, the telehealth platform focused on personalized treatments for hair loss, sexual health, and weight management, reported Q2 2026 results on August 10 with raised full-year revenue guidance to $3.1–3.3 billion amid subscriber growth to nearly 2.9 million. Traders monitoring the next earnings call in November will focus on updates to GLP-1 branded offerings, margin recovery from ongoing investments in AI-driven personalization, diagnostics, and international expansion via the Eucalyptus acquisition. Recent quarters show revenue growth tempered by near-term EBITDA pressure as the company shifts toward higher-margin branded products and platform scaling, creating uncertainty around the pace of profitability improvement and competitive positioning against other digital health providers.